Abstract
The target proteasome has been the focus of drug discovery since the first drug bortezomib was launched in 2003. Many structurally diverse proteasome inhibitors were discovered and even some of them entered the clinical trials. Due to rapid technological progress in chemistry, bioinformatics, structural biology and computer technology, computeraided drug design (CADD) plays a more and more important role in todays drug discovery. Many CADD technologies were employed in designing various inhibitors of proteasome in the past years. This review gives a global description of the development of computer-aided proteasome inhibitor design by using different commercial or academic software. The binding modes of some structurally novel inhibitors with proteasome were visualized with these new technologies.
Keywords: Proteasome inhibitor, Computer-aided drug design, Rational drug design, biological targets, polyubiquitin chains, constitutive proteasome, drug discovery, N-terminal threonine, nucleophilic attack, amide compounds, biologically evaluated, CH hydrogen and electron system, hydrogen bonds, ubiquitin-proteasome pathway
Current Topics in Medicinal Chemistry
Title: Progress of Computer-Aided Drug Design (CADD) of Proteasome Inhibitors
Volume: 11 Issue: 23
Author(s): Meng Lei, Yunde Liu, Yongqiang Zhu and Zhenming Liu
Affiliation:
Keywords: Proteasome inhibitor, Computer-aided drug design, Rational drug design, biological targets, polyubiquitin chains, constitutive proteasome, drug discovery, N-terminal threonine, nucleophilic attack, amide compounds, biologically evaluated, CH hydrogen and electron system, hydrogen bonds, ubiquitin-proteasome pathway
Abstract: The target proteasome has been the focus of drug discovery since the first drug bortezomib was launched in 2003. Many structurally diverse proteasome inhibitors were discovered and even some of them entered the clinical trials. Due to rapid technological progress in chemistry, bioinformatics, structural biology and computer technology, computeraided drug design (CADD) plays a more and more important role in todays drug discovery. Many CADD technologies were employed in designing various inhibitors of proteasome in the past years. This review gives a global description of the development of computer-aided proteasome inhibitor design by using different commercial or academic software. The binding modes of some structurally novel inhibitors with proteasome were visualized with these new technologies.
Export Options
About this article
Cite this article as:
Lei Meng, Liu Yunde, Zhu Yongqiang and Liu Zhenming, Progress of Computer-Aided Drug Design (CADD) of Proteasome Inhibitors, Current Topics in Medicinal Chemistry 2011; 11 (23) . https://dx.doi.org/10.2174/156802611798281366
DOI https://dx.doi.org/10.2174/156802611798281366 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Implication of Platelet Activating Factor in Cancer Growth and Metastasis: Potent Beneficial Role of PAF-Inhibitors and Antioxidants
Infectious Disorders - Drug Targets Expression, Distribution and Regulation of Phosphodiesterase 5
Current Pharmaceutical Design Zinc and Copper Homeostasis in Head and Neck Cancer: Review and Meta-Analysis
Current Medicinal Chemistry Diabetes Mellitus: Channeling Care through Cellular Discovery
Current Neurovascular Research Sumoylation as an Emerging Target in Therapeutics against Cancer
Current Pharmaceutical Design An Overview on Pyranocoumarins: Synthesis and Biological Activities
Current Organic Chemistry Eph/Ephrin Signalling and Function in Oncogenesis: Lessons from Embryonic Development
Current Cancer Drug Targets Role of Iodine in Metabolism
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Recent Advances in the Development of Selective CB2 Agonists as Promising Anti-Inflammatory Agents
Current Medicinal Chemistry Preclinical Development of Novel Anti-Glioma Drugs Targeting the Endoplasmic Reticulum Stress Response
Current Pharmaceutical Design Editorial (Thematic Issue: Combinatorial Fluorophores for Live Cell Imaging)
Combinatorial Chemistry & High Throughput Screening Targeting SP1 Transcription Factor in Prostate Cancer Therapy
Medicinal Chemistry A synopsis on the linkage between age-related dementias and vascular disorders
CNS & Neurological Disorders - Drug Targets Antisense Oligodeoxynucleotide Therapy for Prostate Cancer Targeting Antiapoptotic Genes Involved in the Mechanism Mediating Progression to Androgen Independence
Current Signal Transduction Therapy γ-H2AX as a Therapeutic Target for Improving the Efficacy of Radiation Therapy
Current Cancer Drug Targets Mitochondrial Dysfunction and Lipid Homeostasis
Current Drug Metabolism Humoral and Mechanical Cross-Talk in the Vasculature: Perspectives in Vascular Disease
Vascular Disease Prevention (Discontinued) Current Research on Opioid Receptor Function
Current Drug Targets Targeting Indoleamine 2,3-dioxygenase (IDO) to Counteract Tumour- Induced ImmuneDysfunction: From Biochemistry to Clinical Development
Endocrine, Metabolic & Immune Disorders - Drug Targets A Review of Current Animal Models of Osteoarthritis Pain
Current Pharmaceutical Biotechnology